SANA News and Press, Sana Biotechnology Inc. From 01/07/26

SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT o...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November 2025, as healthcare providers deployed intelligent technologies ac...

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology Broadens Application of Fusogen Technology Beyond T Cells to Second Cell Type, HSCs, Showing Potent and Specific ...

2025-12-03 17:03:25 ET Sana Biotechnology, Inc. (SANA) Evercore 8th Annual Healthcare Conference December 3, 2025 2:35 PM EST... Read the full article on Seeking Alpha For further details see: Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Confere...

2025-12-02 17:43:25 ET Sana Biotechnology, Inc. (SANA) Citi Annual Global Healthcare Conference 2025 December 2, 2025 2:30 PM EST... Read the full article on Seeking Alpha For further details see: Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conf...

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a bu...

2025-11-18 08:42:02 ET Issued on behalf of Avant Technologies Inc. VANCOUVER – USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies race to commercialize therapies that read, replace, and rew...

2025-11-13 15:43:39 ET Investment Overview Zug, Switzerland-based CRISPR Therapeutics AG ( CRSP ) announced its Q3 earnings this Monday, 10th November. The gene therapy company revealed an R&D spend for the quarter of $58.9m, down from $82.2m in the prior year period...

2025-11-06 17:27:09 ET More on Sana Biotechnology Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight Sana Biotechnology, Inc. (SANA) Presents At Morgan St...

Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan, and path to filing SC451 Investigational New Drug Application (IND) as early as 2026 ...